| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Przedborski, V Jackson-Lewis, R Yokoyama, T Shibata, V L Dawson, T M Dawso. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America. vol 93. issue 10. 1996-07-18. PMID:8643444. |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) causes nigrostriatal dopaminergic pathway damage similar to that observed in parkinson disease (pd). |
1996-07-18 |
2023-08-12 |
mouse |
| L Cao, Z C Zheng, Y C Zhao, Z H Jiang, Z G Liu, S D Chen, C F Zhou, X Y Li. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Human gene therapy. vol 6. issue 11. 1996-03-14. PMID:8573622. |
the rotational asymmetry of parkinson disease model rat was reduced quickly and significantly, suggesting that plasmid-dna-transfected brain cells can generate l-dopa locally in the striatum in quantities sufficient to compensate partially for the loss of intrinsic striatal dopaminergic input. |
1996-03-14 |
2023-08-12 |
rat |
| G Nikkhah, A Brandi. [Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system]. Zentralblatt fur Neurochirurgie. vol 56. issue 4. 1996-03-07. PMID:8571693. |
[neurotransplantation in parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system]. |
1996-03-07 |
2023-08-12 |
rat |
| M Asanuma, N Ogawa, S Nishibayashi, M Kawai, Y Kondo, E Iwat. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Archives internationales de pharmacodynamie et de therapie. vol 329. issue 2. 1996-02-06. PMID:8540762. |
further research on the neuroprotective effects of pergolide in parkinson disease models, by injection of 6-hydroxydopamine, is needed to clarify its mechanism of action on dopaminergic indices. |
1996-02-06 |
2023-08-12 |
mouse |
| M Miranda, D Saé. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease]. Revista medica de Chile. vol 123. issue 3. 1996-01-22. PMID:8525172. |
[apomorphine test: evaluation of dopaminergic response in patients with parkinson disease]. |
1996-01-22 |
2023-08-12 |
Not clear |
| B A Faucheux, N Nillesse, P Damier, G Spik, A Mouatt-Prigent, A Pierce, B Leveugle, N Kubis, J J Hauw, Y Agi. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. vol 92. issue 21. 1995-11-14. PMID:7568181. |
the degeneration of nigral dopaminergic neurons in parkinson disease is believed to be associated with oxidative stress. |
1995-11-14 |
2023-08-12 |
human |
| B A Faucheux, N Nillesse, P Damier, G Spik, A Mouatt-Prigent, A Pierce, B Leveugle, N Kubis, J J Hauw, Y Agi. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. vol 92. issue 21. 1995-11-14. PMID:7568181. |
these data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in parkinson disease. |
1995-11-14 |
2023-08-12 |
human |
| D M Frim, T A Uhler, W R Galpern, M F Beal, X O Breakefield, O Isacso. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United States of America. vol 91. issue 11. 1994-06-27. PMID:8197193. |
the trophism of brain-derived neurotrophic factor (bdnf) for dopaminergic cells in culture has led to significant interest in the role of bdnf in the etiology and potential treatment of parkinson disease. |
1994-06-27 |
2023-08-12 |
human |
| D M Frim, T A Uhler, W R Galpern, M F Beal, X O Breakefield, O Isacso. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United States of America. vol 91. issue 11. 1994-06-27. PMID:8197193. |
the observation that bdnf prevents mptp-induced dopaminergic neuronal degeneration in the adult brain has significance for the treatment of neurodegenerative disorders, which may involve mitochondrial dysfunction, such as parkinson disease. |
1994-06-27 |
2023-08-12 |
human |
| T Hagg, S Varo. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proceedings of the National Academy of Sciences of the United States of America. vol 90. issue 13. 1993-08-06. PMID:8101002. |
thus, cntf has potent neurotrophic effects for injured adult rat dopaminergic substantia nigra neurons, whose degeneration plays a major causative role in parkinson disease. |
1993-08-06 |
2023-08-12 |
human |
| R R Bowsher, J M Apathy, J A Compton, R L Wolen, K H Carlson, K A DeSant. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma. Clinical chemistry. vol 38. issue 10. 1992-11-16. PMID:1394981. |
pergolide, a synthetic ergoline with potent dopaminergic activity, is used to treat parkinson disease. |
1992-11-16 |
2023-08-11 |
rat |
| M Zabek, W Mazurowski, J Dymecki, J Stelmachów, B Gawur, W Trautsolt, E Zawad. [Transplantation of fetal dopaminergic cells in Parkinson disease]. Neurologia i neurochirurgia polska. vol Suppl 1. 1992-10-26. PMID:1407286. |
[transplantation of fetal dopaminergic cells in parkinson disease]. |
1992-10-26 |
2023-08-11 |
Not clear |
| F Baronti, S Ruggieri, M M Mouradian, A Bonamartini, P Bocciarelli, M F De Pandis, T N Chase, A Agnol. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]. Rivista di neurologia. vol 61. issue 6. 1992-06-12. PMID:1813972. |
[changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in parkinson disease]. |
1992-06-12 |
2023-08-11 |
Not clear |
| A Dahlström, A Wigander, K Lundmark, C G Gottfries, P M Carvey, A McRa. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. Journal of neural transmission. Supplementum. vol 29. 1990-08-01. PMID:2358801. |
in immunocytochemical studies, the csf from parkinson disease (pd) patients and from alzheimer disease (ad) patients were investigated for the presence of neuron specific antibodies using dopaminergic and cholinergic neuronal cultures from embryonic rat brain, respectively. |
1990-08-01 |
2023-08-11 |
rat |
| J A Obeso, M R Luquin, J Vaamonde, F Grandas, M A Pastor, J Artieda, J M Martínez-Lag. [Continuous dopaminergic stimulation in Parkinson disease]. Neurologia (Barcelona, Spain). vol 2. issue 5. 1990-07-20. PMID:2908545. |
[continuous dopaminergic stimulation in parkinson disease]. |
1990-07-20 |
2023-08-11 |
Not clear |
| M B Spina, G Cohe. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. vol 86. issue 4. 1989-03-27. PMID:2919185. |
parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract. |
1989-03-27 |
2023-08-11 |
mouse |
| B Dubois, Y Agi. [Dopaminergic agonists in Parkinson disease]. La Revue du praticien. vol 36. issue 5. 1986-04-29. PMID:3961400. |
[dopaminergic agonists in parkinson disease]. |
1986-04-29 |
2023-08-11 |
Not clear |
| S I Harik, J C LaManna, S Snyder, J R Wetherbee, M Rosentha. Abnormalities of cerebral oxidative metabolism in animal models of Parkinson disease. Neurology. vol 32. issue 4. 1982-05-27. PMID:6278364. |
we speculate that the dementia of parkinson disease may be more prevalent when degeneration of catecholaminergic systems is widespread and not restricted to the dopaminergic system. |
1982-05-27 |
2023-08-12 |
rat |
| C G Goetz, C M Tanner, P A Nausied. Weekly drug holiday in Parkinson disease. Neurology. vol 31. issue 11. 1982-02-25. PMID:7031503. |
patients with parkinson disease and drug-related side effects entered an open-trial study in which they stopped all dopaminergic medications for 2 consecutive days each week. |
1982-02-25 |
2023-08-12 |
Not clear |
| V W Henderson, G F Woote. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. vol 31. issue 2. 1981-04-13. PMID:6110195. |
in a patient with parkinson disease and a chronic psychiatric disorder treated with haloperidol, typical features of nms appeared upon cessation of dopaminergic antiparkinsonian drugs. |
1981-04-13 |
2023-08-12 |
Not clear |